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Active supportive careExperimental design: We conducted a randomised double-blind trial among patients with un-
treated advanced NSCLC considered unfit for platinum chemotherapy because of poor perfor-
mance status (PS) or multiple comorbidities. All patients received active supportive care
(ASC) and were treated with either oral erlotinib or placebo daily. Five hundred twenty-
seven patients had plasma samples for VeriStrat classification: good (VeriStrat Good
[VSG]) or poor (VeriStrat Poor [VSP]). Main end-point was overall survival.
Results: Fifty-five percent patients had VSG, and 83% had Eastern Cooperative Oncology
Group (ECOG) 2e3 at baseline. VeriStrat was strongly associated with survival. Among pa-
tients managed with ASC only, the adjusted hazard ratio (HR) was 0.54 (p < 0.001) for VSG
versus VSP. The association was consistent across patient factors: HRZ 0.25 (pZ 0.004) and
HRZ 0.56 (p < 0.001) for ECOG 0e1 and 2e3, respectively, HRZ 0.49 (0070 < 0.001) for
age75 years and HRZ 0.59 (pZ 0.007) for stage IV. Several ECOG 2e3 patients had long
survival: 2-year survival was 8% for VSG patients who had ASC, compared with 0% for VSP.
VeriStrat status did not predict benefit from erlotinib treatment because the HRs for erlotinib
versus placebo were similar between VSG and VSP patients.
Conclusions: VeriStrat was not a predictive marker for survival when considering first-line er-
lotinib for patients with NSCLC who had poor PS and were not recommended for platinum
doublet therapies. However, VeriStrat was an independent prognostic marker of survival. It
represents an objective measurement that could be considered alongside other patient factors
to provide a more refined assessment of prognosis for this particular patient group. VSG pa-
tients could be selected for treatment trials because of better survival, while VSP patients can
continue to be treated conservatively or offered trials of less toxic agents.
Trial registration ISRCTN Number: ISRCTN02370070.
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Despite major advances made recently with immuno-
therapies for advanced nonesmall cell lung cancer
(NSCLC), optimal treatment of patients with poor
performance NSCLC (Eastern Cooperative Oncology
Group, [ECOG] performance status [PS] 2) remains
undefined, even though they represent a significant
undertreated population with unmet need. In the 2018
UK National Lung Cancer Audit Annual Report, 41%
of the 39,199 patients newly diagnosed in the UK were
classified as having poor PS (ECOG 2) (Reference:
https://www.rcplondon.ac.uk/projects/national-lung-
cancer-audit). We previously demonstrated that the
median survival of poor prognosis NSCLC patients
considered unfit for first-line platinum chemotherapy
was <4 months, from our multicentre TOPICAL
phase III trial [1]. The significant progress using first-
line immunotherapies, with or without platinum-based
chemotherapy, is mainly confined to patients with
good PS (ECOG 0e1).
Oral epidermal growth factor receptor (EGFR)
tyrosine-kinase inhibitors (TKIs) including gefitinib,
erlotinib and afatinib are established as first-line agents
for EGFR-mutant advanced NSCLC and as subsequent
lines of therapy for relapsed wild-type patients previously
treated with immunotherapy and chemotherapy [28].
VeriStrat (Biodesix, USA) is a commercially
available proteomic test [9] to identify patients likely or
unlikely to benefit from TKI treatment. Usingpretreatment serum or plasma samples, this test assigns
patients to either ‘VeriStrat Good (VSG)’ or ‘VeriStrat
Poor (VSP)’ status, as an indicator of prognosis and
response to treatment. The test uses matrix-assisted
laser desorption/ionisation time of flight (MALDI-
TOF) mass spectrometry and compares the intensity of
eight mass spectral features with the intensity of those
of a reference set [9].
Several studies show that VeriStrat is a prognostic
marker such that VSG patients have better outcomes
including survival than VSP patients [924]. However,
the vast majority of the patients included in these studies
had predominantly good PS (ECOG 0e1). Only one
study included some patients who had poor status
(ECOG 3) [10], and it cannot be assumed that the same
prognostic relationship holds for these particular
patients.
The TOPICAL trial [1] was based on patients with
advanced NSCLC considered unfit for first-line plat-
inum-based chemotherapy, primarily because of having
poor PS (83% were ECOG 2, including 29% who were
ECOG 3) or multiple comorbidities. The primary aim in
this article is to examine the prognostic value of Ver-
iStrat in the half of patients who received standard
active supportive care (ASC) only, including palliative
radiotherapy (i.e. the placebo arm). This could identify
patient subgroups with better or worse outcomes, who
might then be managed differently by their clinician
compared with the traditional selection criteria based
mainly on PS as a prognostic selection marker.
Table 1
Baseline characteristics in the 527 patients classified as having a VeriStrat Poor or Good status.
Characteristics VeriStrat Poor
N Z 239
VeriStrat Good
N Z 288
P-value for differenceb
Age at entry, median (range) 76 (51e90) 78 (51e91) 0.006
Sex Number of patients (%)
Male 159 (66.5) 156 (54.2) 0.004
Female 80 (33.5) 132 (45.8)
ECOG performance status
0-1 (only 9 ECOG 0) 32 (13.4) 57 (19.8) 0.06
2 133 (55.6) 162 (56.2)
3 74 (31.0) 69 (24.0)
Stage
IIIB 93 (38.9) 92 (31.9) 0.10
IV 146 (61.1) 196 (68.1)
Histology
Adenocarcinoma 66 (27.6) 129 (44.8) <0.001
Squamous 121 (50.6) 93 (32.3)
Other 52 (21.8) 66 (22.9)
Smoking status
Current smoker 89 (37.2) 100 (34.7) 0.14
Former smoker 142 (59.4) 167 (58.0)
Never smoked 8 (3.4) 21 (7.3)
Known EGFR status n Z 144 n Z 166 0.006
Mutant positive 6 (4.2) 21 (12.6)
Wild-type 138 (95.8) 145 (87.4)
Trial treatment 0.04
Erlotinib 115 (48.1) 164 (56.9)
Placebo 124 (51.9) 124 (43.1)
Rash statusa n Z 197 n Z 267 0.12
Placebo 103 (52.3) 114 (42.7)
No rash (erlotinib) 39 (19.8) 65 (24.3)
Rash (erlotinib) 55 (27.9) 88 (33.0)
ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor.
a First-cycle rash in the erlotinib group (among patients who started treatment and alive at 28 days).
b P-value for the difference between VeriStrat Poor and Good.
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TOPICAL represents a unique study population
because all patients were chemotherapy naı¨ve (so no
potential interaction effects of prior cytotoxic therapy);
and most (83%) had poor PS status (ECOG 2e3)
reflecting real-world practice.
2.1. Patients and procedures
TOPICAL has been described before [1]. Newly diag-
nosed patients with stage IIIB/IV NSCLC were consid-
ered unfit for first-line platinum-based doublet
chemotherapy because of ECOG 2e3 and/or they had
multiple comorbidities. Majority of patients had EGFR
wild-type tumours [1]. All patients received ASC
including palliative radiotherapy for symptomatic sites.
They were randomised to 150-mg oral erlotinib or pla-
cebo daily, until progressive disease or toxicity. They
attended clinic every month in the first year, then every 2
months thereafter. Computed tomography scans were
performed at 3 and 6 months and when clinically indi-
cated. Rash was graded using the following criteria:
erythema alone, erythema with papules, erythema withpapules and pustules and erythema with papules and
confluent pustules. Patients were categorised as having
first-cycle rash when any of the above symptoms were
diagnosed approximately one month after starting
erlotinib treatment.
Before starting erlotinib/placebo, patients provided a
10-ml blood sample, collected in an ethylene diamine
tetra-acetic acid tube, which was posted immediately to
the central laboratory at University College London,
where plasma aliquots were stored at 80 C. Samples
were later tested with VeriStrat by the Biodesix labora-
tory (US), where personnel were blinded to patient/
tumour characteristics and outcomes [9]. Of 670
TOPICAL patients, 535 had plasma samples available;
of which, 8 had an indeterminate VeriStrat
classification.
2.2. Statistical methods
The primary trial end-point was overall survival (OS),
measured from the date of randomisation until death
from any cause. Progression-free survival (PFS) was
measured from randomisation until Response Evalua-
tion Criteria in Solid Tumours (RECIST) progression or
S.M. Lee et al. / European Journal of Cancer 120 (2019) 86e96 89death from any cause. Patients who did not die, or did
not have a PFS event, were censored at the date they
were last known to be alive.
We evaluated two potential clinical uses of the Ver-
iStrat test separately: as a (i) prognostic marker or (ii)
predictive biomarker for erlotinib relative to placebo.
KaplaneMeier curves and Cox proportional uni-
variable and multivariable hazards regression were used
to examine the association between VeriStrat status and
OS and PFS, using hazard ratios (HRs), including
adjustment for patient and tumour characteristics. The
prognostic value of VeriStrat was determined by exam-
ining the HR for VSG versus VSP. The predictive value
of VeriStrat was determined by examining the HR for
erlotinib versus placebo in each VeriStrat status
group and tested using an interaction term between
treatment and VeriStrat status. Various exploratory
subgroup analyses were carried out, but no allowance
was made for multiple testing.
3. Results
Baseline characteristics did not differ between the 527
(out of 670 total) patients contributing to the analyses
below and the 143 who were not included (either no
blood sample available for VeriStrat testing, or the 8
patients who had an indeterminate VS status). Fifty-five
percent (288/527) of patients had VSG status (Table 1).
Eighty-three percent (438/527) had ECOG 2e3
(including 143 with ECOG 3). The proportion with VSP
increased with worsening PS: 36% (32/89), 45% (133/
295) and 52% (74/143) for ECOG 0e1, 2 and 3,
respectively (trend p Z 0.02). Five hundred eighteenFig. 1. VeriStrat as a prognostic marker: KaplaneMeier curves for Ve
patients had active supportive care only). The unadjusted hazard ratio
Table 3). CI, confidence interval; OS, overall survival.patients had died (most due to lung cancer), and 523 had
progressed or died (PFS event). Four hundred forty
patients received additional anticancer therapies; of
which, at least 195 had palliative radiotherapy.
3.1. VeriStrat as a prognostic biomarker in patients who
had ASC only
Patients who had ASC only (i.e. placebo) who were
classified as VSG had much better OS and PFS than
those with VSP classification (Fig. 1). The median OS
was 4.6 months for VSG (95% CI 3.3e6.9), compared
with 2.9 months VSP (95% CI 2.3e3.5), with HR 0.54;
46% reduction in mortality (p < 0.001). VeriStrat can
identify a subgroup of patients who have better out-
comes in those who do not receive systemic therapies.
We noted the relatively long survival for several VSG
patients (Fig. 1). The 2-year survival rates (ASC only)
were 7.6% (95% CI 2.8e12.4) for VSG patients but 0%
for VSP patients. At 3 years, the rate was 2.9% for VSG.
Fig. 2 shows the results separately by baseline ECOG
status, age, stage and histology (these subgroup HRs
could form a forest plot, but we want to show the whole
OS curves to visualise the tails). There were strong asso-
ciations between VeriStrat status and OS, regardless of
ECOG. The HRs were 0.25 for ECOG 0e1 (75% reduc-
tion in mortality or striking difference in medianOS from
3.4 to 10.5 months) and 0.56 for ECOG 2e3 (44% mor-
tality reduction or difference inmedianOS from 3.6 to 4.4
months). Some VSG patients with ECOG 2e3 demon-
strated very long survival, even among those who were
considered to have the worse prognosis at baseline. The 2-
year survival rate for ASC only patients with ECOG 2e3riStrat Good and Poor according to the treatment group (placebo
s (HRs) for VeriStrat Good vs. Poor are shown (adjusted HRs in
Fig. 2. A. VeriStrat as a prognostic marker among patients who had active supportive care only, according to ECOG and age: Overall
survival for VeriStrat Good (solid line) and Poor (dashed line). Hazard ratios (HRs) for VeriStrat Good vs. Poor are shown (adjusted for
age, sex, ECOG, stage, histology and smoking, excluding the factor of interest). The HRs in square brackets are when EGFR-positives are
excluded. Fig. 2B. VeriStrat as a prognostic marker among patients who had active supportive care only, according to histology and stage:
Overall survival for VeriStrat Good (solid line) and Poor (dashed line). Hazard ratios (HRs) for VeriStrat Good vs. Poor are shown
(adjusted for age, sex, ECOG, stage, histology and smoking, excluding the factor of interest). The HRs in square brackets are when
EGFR-positives are excluded.
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for VSP. In addition, the adjusted HRs (VSG vs. VSP)
were 0.45 (95% CI 0.27e0.75, pZ 0.002) and 0.63 (95%
CI 0.42e0.94, p Z 0.02) for females and males,
respectively.
Furthermore, the clear separation between VSG and
VSP patients was seen in different age groups, with a large
effect (HR 0.49, p < 0.001) even among older patients,
75 years, and with a very long tail for VSG patients
(Fig. 2A), similarly for stage, where the VSG vs. VSP HR
for stage IV patients was 0.59 (pZ 0.007), and again some
VSGpatients demonstrated longOS (Fig. 2B).All of these
subgroup comparisons were statistically significant.
Table 2 summarises OS among specific factors
indicative of poor prognosis, with and without consid-
eration of the VeriStrat test. For example, median OS
for patients with ECOG 2e3 is 3.8 months, but patients
who are also VSG have a median OS of 4.4 months. The
corresponding 1-year OS rate increases from 12 to 17%,
respectively. The effect was more pronounced for elderly
patients. The median OS for all patients 75 years was
4.3 months, compared with 5.6 months if they were
VSG; and the 1-year OS rate increases from 19 to 29%,
whereas the 2-year rate almost doubles from 5 to 9%. In
each of these high-risk groups (ECOG 2e3, elderly, or
stage IV), about half of patients are classified as VSG,
representing a significant number of patients whose
treatment plan could be adapted accordingly, because
their outcomes are noticeably better than expected.
Similarly, if patients had been classified as VSP the
median OS and 1 and 2-year survival rates were all
clearly lower than when ignoring VeriStrat status. Re-
sults were similar after excluding patients with EGFR-
positive tumours.
3.2. VeriStrat as a prognostic biomarker in all patients
We analysed all patients together because this provides
additional information on the variability of the factors
examined to support the assessment of VeriStrat as a
prognostic marker. Table 3 shows that VeriStrat and
ECOG were independent risk factors with the strongest
association with both OS and PFS. Stage and histology
were also statistically significantly associated with out-
comes. The adjusted OS HR was 0.58 (VSG versus
VSP), similar to 0.54 for ASC patients only, and for
PFS, it was 0.67, representing a 42% and 33% reduction
in risk, respectively (both p < 0.001). These effects were
after allowance for the treatment group, ECOG and age.
The results were generally similar when only analysing
the 283 patients known to have EGFR wild-type tu-
mours (adjusted OS HR 0.53 p < 0.001, and adjusted
PFS HR 0.68 p Z 0.003) and when differentiating pa-
tients who did or did not develop first-cycle rash after
receiving erlotinib (Supplemental Table 1). VeriStrat
and ECOG were the two strongest prognostic factors for
OS/PFS.3.3. VeriStrat as a prognostic biomarker in patients given
erlotinib
For completeness, we also examined the prognostic role
of VeriStrat among the trial patients who received
erlotinib, acknowledging that erlotinib is currently only
used for patients harbouring EGFR activating
mutations. Median survival in our predominantly
EGFR wild-type patients treated with erlotinib was 4.9
months (VSG; 95% CI 3.9e6.6) and 3.1 (VSP; 95% CI
2.1e3.8), with HR 0.60 (40% mortality reduction),
p < 0.001; Fig. 1. As with patients who had ASC
only, the VeriStrat test can clearly distinguish between
good and poor prognosis patients receiving erlotinib.
VSG patients almost always had better outcomes than
VSP patients, which were seen across ECOG, age, stage
and histology (Supplemental Figs. 1e4).
3.4. VeriStrat as a predictive biomarker
VeriStrat could not identify patients who might benefit
from first-line erlotinib in the TOPICAL patients
(Supplemental Table 2). The HRs for erlotinib versus
placebo were generally similar between the VSG and
VSP groups, even when first-cycle rash was taken into
account. Among patients who had erlotinib and devel-
oped first-cycle rash, the HR was 0.75 (95% CI
0.56e1.00) if they were classified as VSG and 0.71 (95%
CI 0.50e1.02) if they were classified as VSP, that is, the
benefit seen with erlotinib was independent of the Ver-
iStrat status. Similarly, the corresponding HRs for
erlotinib patients who did not develop first-cycle rash
were 1.34 (95% CI 0.96e1.87) and 1.19 (95% CI
0.81e1.76). The test for interaction between erlotinib
rash status and VeriStrat was not statistically significant
(pZ 0.82). The same conclusions were made when only
analysing the 283 patients known to have had EGFR
wild-type tumours (Supplemental Table 2).4. Discussion
TOPICAL is the largest randomised trial to evaluate
VeriStrat in a group of patients with an expected poor
prognosis, considered unfit for first-line platinum-based
chemotherapy (median OS less than 4 months). VeriStrat
was an independent prognostic biomarker for bothOSand
PFS in this poor prognosis group who were often unfit,
elderly (median Z 77 years) and with multiple comor-
bidities. Patients with VSG status were 42% less likely to
die (OS HRZ 0.58) or 33% less likely to progress or die
(PFS HRZ 0.67), than those with VSP status. These are
large clinical effects, not often seen with traditional prog-
nostic markers. Our findings could similarly apply to pa-
tients considered unfit for first-line treatment with a check-
point inhibitor, combination check-point inhibitors or in
combination with platinum-doublet therapy.
Table 2
Comparison of overall survival (OS) without or with VeriStrat statusdwhen considering specific factors associated with poor prognosis and
histology, all patients had active supportive care only.
Survival All patients (ignoring VeriStrat) VeriStrat Good VeriStrat Poor % with VeriStrat Good
Age 75 years (n Z 143)
Median OS, months 4.3 [4.1] 5.6 3.4 58
1-year rate (95% CI) 19 (12e25) [17] 29 (19e38) [26] 5 (0e10)
2-year rate (95% CI) 5 (1e9) [4] 9 (3e15) [7] 0
ECOG 2e3 (n Z 177)
Median OS, months 3.8 4.4 3.6 50
1-year rate 12 (7e17) 17 (9e25) 7 [1e12]
2-year rate 4 (1e7) 8 (2e14) [7] 0
Stage IV (n Z 140)
Median OS, months 3.4 [3.3] 4.3 [4.1] 2.8 54
1-year rate 11 (6e16) [9] 18 (9e26) [15] 3 (0e7)
2-year rate 4 (1e7) [2] 7 (1e14) [4] 0
Adenocarcinoma (n Z 77)
Median OS, months 4.1 [3.9] 5.6 3.6 60
1-year rate 11 (4e18) [9] 19 (7e30) [15] 0
2-year rate 5 (1e12) [3] 8 (1e16) [5] 0
Squamous cell (n Z 95)
Median OS, months 4.6 5.3 [6.3] 4.2 [4.4] 43
1-year rate 22 (14e30) [20] 32 (17e46) 11 (3e19)
2-year rate 3 (0e7) [3] 7 (0e15) 0
ECOG, Eastern Cooperative Oncology Group; CI, confidence interval.
The aforementioned results were the same when patients with EGFR positive tumours were excluded, except where shown in square brackets.
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group in TOPICAL). Using the ECOG scale to assess PS
in advanced NSCLC is routine practice to select patients
clinically fit to receive systemic treatment. Because
NSCLC patients with ECOG 2e3 have limited survival,
they are usually excluded from many first-line chemo-
therapy and immunotherapy combination trials. How-
ever, a major finding from TOPICAL is that even within
this poor performance population (83%hadECOG2e3),
the VeriStrat test can further distinguish patients who
have a shorter or longer survival. This has never been
reported before.
Table 4 summarises the randomised trials and obser-
vational studies of VeriStrat as a prognostic marker,
including TOPICAL which is the third largest study.
Although there are various treatment regimens, the
studies consistently show that VSG patients have better
OS and PFS thanVSP patients, with allHRs less than one
[924]. However, all studies recruited patients with pre-
dominantly good PS, and most had already been previ-
ously treated. Only one study included some patients who
had ECOG 3 [10], but even these only represented a
fraction of the patients (33% of all study patients had
ECOG 2e3), and they all had prior chemotherapy. The
TOPICAL trial stands out from the rest, with 56% who
had ECOG 2 and 27% with ECOG 3, and no patient had
prior systemic treatment. The percentage of patients
classified as VSGwas generally lower in TOPICAL (55%)
than the other trials (61e72%), which reflects the modest
correlation between VeriStrat status and ECOG score.
In TOPICAL, both ECOG and VeriStrat were inde-
pendent markers of prognosis and could be consideredtogether to provide a more accurate clinical picture than
either on their own. The ability of VeriStrat to distin-
guish patients who have better or worse survival was
consistently seen among traditional adverse risk factors
(e.g. elderly patients, or stage IV disease). VeriStrat
possibly captures a disease-related additional immune
and proinflammatory profile in the blood [25] that
confers a survival advantage and is a more sensitive and
objective marker than consideration of ECOG status,
which is affected by clinician subjectivity and personal
interpretation. The value to patients and clinicians is
that consideration of ECOG 2 or 3 alone could under-
estimate their actual prognosis. The relative effects
(HRs) and absolute risk differences at 1 and 2 years
(Table 2) are in line with those seen with new lung
cancer treatments in the last few years.
For patients who would usually receive ASC alone
including palliative radiotherapy, VeriStrat could be
used as a selection biomarker together with ECOG
status. Those classified as VSG, even if they have poor
ECOG status or are elderly, could potentially be treated
more aggressively with well-tolerated, newer generation
systemic agents or selected for experimental treatment
trials compared with conventional approach. Given that
about half of patients tested would be classified as VSG,
this represents a significant number who might be given
a different treatment plan and treated more aggressively
than if they were not tested. VSP patients could be
treated more conservatively because of their very poor
outcomes. Alternatively, VSP patients might also be
considered for less toxic experimental trials (e.g.
immunomonotherapies) to attempt to improve their
Table 3
Multivariable Cox regression analyses showing the association between each factor and overall or progression-free survival, including the
VeriStrat test as a prognostic biomarker.
Factor Overall survival hazard ratio (95% CI),
p-value
Progression-free survival hazard ratio
(95% CI), p-value
Ignoring first-cycle rash
VeriStrat (Good vs. Poor) 0.58 (0.48e0.70) <0.001 0.67 (0.56e0.81) <0.001
Treatment (erlotinib vs. placebo) 0.93 (0.87e1.11) 0.41 0.85 (0.71e1.02) 0.08
Age 1.00 (0.99e1.02) 0.74 1.00 (0.99e1.02) 0.51
Sex (females vs. males) 0.82 (0.68e0.98) 0.03 0.78 (0.65e0.94) 0.009
ECOG
0-1 1.0 <0.001 1.0 <0.001
2 1.30 (1.01e1.67) 1.11 (0.87e1.43)
3 2.04 (1.53e2.72) 1.85 (1.39e2.47)
Stage (IV vs. IIIB) 1.21 (1.00e1.46) 0.04 1.23 (1.02e1.48) 0.03
Histology
Squamous 1.0 0.02 1.0 0.05
Adenocarcinoma 1.26 (1.02e1.55) 1.16 (0.95e1.43)
Other 1.34 (1.07e1.69) 1.33 (1.06e1.68)
Smoking status
Never/former smoker 1.0 0.25 1.0 0.30
Current smoker 1.12 (0.92e1.35) 1.10 (0.92e1.33)
EGFR (positive vs wild-type) 0.53 (0.33e0.83) 0.006 0.65 (0.42e1.01) 0.06
Allowing for first cycle rash
VeriStrat (Good vs. Poor) 0.61 (0.50e0.74) <0.001 0.71 (0.58e0.87) <0.001
Treatment
Placebo 1.0 <0.001 1.0 0.002
Erlotinib, no rash 1.29 (1.01e1.65) 1.07 (0.84e1.37)
Erlotinib, rash 0.76 (0.61e0.94) 0.71 (0.57e0.89)
Age 1.00 (0.99e1.02) 0.67 1.01 (0.99e1.02) 0.48
Sex (females vs. males) 0.83 (0.68e1.01) 0.06 0.82 (0.67e0.99) 0.04
ECOG
0-1 1.0 0.001 1.0 0.004
2 1.26 (0.97e1.63) 1.07 (0.83e1.38)
3 1.75 (1.28e2.38) 1.55 (1.14e2.11)
Stage (IV vs. IIIB) 1.29 (1.06e1.57) 0.01 1.31 (1.07e1.59) 0.008
Histology
Squamous 1.0 0.10 1.0 0.22
Adenocarcinoma 1.20 (0.96e1.51) 1.10 (0.88e1.37)
Other 1.28 (1.00e1.64) 1.25 (0.97e1.60)
Smoking status
Never/former smoker 1.0 0.31 1.0 0.25
Current smoker 1.11 (0.90e1.36) 1.13 (0.92e1.38)
EGFR (positive vs wild-type) 0.55 (0.34e0.89) 0.01 0.70 (0.44e1.11) 0.13
ECOG, Eastern Cooperative Oncology Group; CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio.
Each HR is adjusted for all the other factors in the table except for EGFR status (because there were only 27 who were EGFR positive). The HRs
for EGFR status are from a separate multivariable Cox regression which contains all the factors in the table.
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mab or other single agent [26].
First-line erlotinib is currently only recommended for
treating advanced NSCLC patients with common
EGFR activating mutation. Therefore, our analyses
relating to VeriStrat as a predictive biomarker for
erlotinib was for research interest only, simply because
we had a group of poor PS patients who received erlo-
tinib whom we previously demonstrated that patients
who developed first-cycle rash was associated with
improved OS compared to placebo (HRZ0.76) [1].
However, we showed that VeriStrat was not a predictive
marker for first-line erlotinib in our predominantly
EGFR wild-type particular patient group, even when
first-cycle rash was taken into account. Median OS was4.9 months (erlotinib) and 4.6 months (placebo) among
VSG patients, and for VSP patients they were 3.1 and
2.9 months respectively (Fig. 1). This is consistent with
several randomised studies of pretreated patients
[10,11,14,16], while two other trials of second line ther-
apy found evidence of the (negative) predictive value of
VeriStrat, but all of these studies were conducted among
primarily good PS patients [13,14].
A limitation of TOPICAL was that we included pa-
tients with ECOG2whomight now be treated with newer
generation single-agent cytotoxic agents, but when
TOPICAL was planned in 2002, provision of chemo-
therapy to such poor prognosis patients was not routine
practice because many studies of second-/third-genera-
tion chemotherapy agents did not improve survival, and
Table 4
Summary of clinical trials and observational studies that have examined the prognostic association between the VeriStrat test in advanced NSCLC (stage IIIb/IV, progressive/recurrent disease) and
outcomes, including TOPICAL.
Hazard ratio for Good vs Poor (95% CI)a
Reference (first author) Treatment Line of therapy Number
patients
% with PS 2 % with
VeriStrat ‘Good’
Overall survival Progression-free survival
Randomised clinical trials
Carbone 2012 [10] Erlotinib vs placebo Second/third 436 33 (PS 2e3) 61 0.67 (0.45e1.01)b 0.56 (0.40e0.80)b
10.5 vs 4.0 monthsc 3.7 vs 1.8 monthsc
Peters 2007 [11] Erlotinib vs docetaxel Second 80e 9 72 0.49 (0.28e0.86)# 0.73 (0.44e1.22)#
Stinchcombe 2013 [12] Gemcitabine vs erlotinib vs both First 98 28 64 0.53 (0.32e0.90) 0.51 (0.30e0.86)
Gregorc 2014 [13] Erlotinib vs pemetrexed or docetaxel Second 263 6 70 0.53 (0.35e0.80) 0.57 (0.44e0.75)#
Gadgeel 2017 [14] Erlotinib vs afatinib Second 675 0.3 61 0.41 (0.35e0.49) 0.65 (0.54e0.77)
Spigel 2018 [15] Erlotinib vs placebo (all had pazopanib) Second/third 88 14 72 0.42 (0.26e0.69)# 0.44 (0.26e0.73)#
Buttigliero 2019 [16] Tivantinib vs placebo (all had erlotinib) Second/third 996 0.2 72 Tiva: 0.33 (0.26e0.42)#
Plac: 0.45 (0.35e0.58)#
0.52 (0.40e0.67)
TOPICAL trial Erlotinib vs placebo First 527 56%
(plus 27% PS 3)
55 0.58 (0.48e0.70) 0.67 (0.56e0.81)
Single-arm clinical trials
Taguchi 2007 [9] Erlotinib First 96 26 72 0.53 (0.30e0.94) 0.53 (0.33e0.85)#
Amann 2010 [17] Erlotinib First 88 25 73 0.44 (0.18e1.08) 0.51 (0.28e0.90)#
Carbone 2010 [18] Erlotinib þ bevacizumab Second 34 0 76 0.14 (0.03e0.58)# 0.04 (0.01e0.24)#
Dingemans 2012 [19] Sorafenib 1 prior line 55f 5 58 0.77 (0.59e1.11)# 0.71 (0.53e1.0)#
Kuiper 2012 [20] Erlotinib þ sorafenib First 50 0 66 0.30 (0.12e0.74)# 0.40 (0.17e0.94)#
Akerley 2013 [21] Erlotinib þ bevacizumab First 41 0 76 16.5 vs 4.6 monthsd 4.4 vs 1.4 monthsd
Gautschi 2013 [22] Erlotinib þ bevacizumab First 114 5 76 0.48 (0.29e0.78)# 0.77 (0.48e1.22)#
Observational studies
Taguchi 2007 [9] Gefitinib  second 67 24 58 0.74 (0.55e0.99) 0.56 (0.28e0.89)#
Lazzari 2012 [23] Gefitinib 1 prior line 108 18 69 0.44 (0.26e0.72) 0.52 (0.30e0.92)
Grossi 2016 [24] Pemetrexed þ platinum First 76 3 66 0.23 (0.11e0.46) 0.39 (0.22e0.71)
ECOG, Eastern Cooperative Oncology Group; CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio; OS, overall survival; PS, performance status.
None of the studies except Carbone 2012 and TOPICAL included patients with PS 3.
a Adjusted HRs (for various patient/tumour characteristics), except where indicated by # which are unadjusted HRs.
b Placebo group only.
c Median OS (or PFS) among patients with Good vs Poor VeriStrat, all received erlotinib.
d Median OS (or PFS) among patients with Good vs Poor VeriStrat.
e Not EGFR positive.
f All had KRAS mutant tumours.
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ated with platinum-based chemotherapy. Another limi-
tation was that EGFR status was not assessed on all trial
patients which is now standard practice, an important
consideration when examining VeriStrat as a predictive
biomarker for an EGFR inhibitor and as a prognostic
marker when analysing all patients together. Neverthe-
less, of the 670 patients randomised for the TOPICAL
trial, tumour DNA was available for 390 patients (58%);
and the incidence of EGFRmutation was only 7% (with a
quarter classified as uncommon EGFR mutations),
whereas the rest were EGFR wild-type NSCLC as re-
ported previously [1]. Our results were very similar when
only examining patients with known EGFR wild-type
tumours (Supplemental Tables 1e2).
In conclusion, TOPICAL shows thatVeriStrat was not
a predictive marker for first-line erlotinib in our trial.
However, we provide new evidence on the added clinical
value of VeriStrat in a major EGFR wild-type NSCLC
elderly population with poor PS and multiple comor-
bidities, unfit for first-line combination systemic therapy.
Among patients whomight receiveASC only, VeriStrat is
an objective and reproducible measurement that is
strongly associated with OS. It could add value to other
clinical parameters including PS to aid patient selection
and management by identifying longer term survivors
who might be able to tolerate and benefit from appro-
priate upfront therapies or selection for treatment trials.
While patients who have a poorer prognosis could have
conservative treatments or be offered interventional trials
with agents known to have relatively little toxicity, cost-
effective studies on the use of VeriStrat as a selection
marker would be useful.
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